Search contract descriptions, companies and agencies.
CHARACTERIZE SEROPREVALENCE OF SARS COV-2 ANTIBODIES IN THE US POPULATION
Total Committed
$32.7M
Product or Service Description
Biomedical R&D
Total Potential Value
$32.7M
Contracting Agency
Effective Date
May 12, 2020
Funding Department
CDC OFFICE OF ACQUISITION SERVICES
Type
Cost no fee
Solicitation Procedure
Basic research
Extent Competed
Full and open competition
Recent Contract Actions 
Contracts can have multiple “contract actions”: This is how agencies spend money for a specific purpose, adjust the amount committed or change the contract in a way that doesn’t affect the amount. That last scenario is usually indicated by a $0 action. If there is a contract action for a negative amount, it generally means the contract was adjusted or canceled.
| Vendor | Description | Signed | Reason for Change | Amount Committed |
|---|---|---|---|---|
| VITALANT | CHARACTERIZE SEROPREVALENCE OF SARS COV-2 ANTIBODIES IN THE US POPULATION | March 11, 2021 | Supplemental Agreement For Work Within Scope | $11,221,162 |
| VITALANT | CHARACTERIZE SEROPREVALENCE OF SARS COV-2 ANTIBODIES IN THE US POPULATION | Aug. 12, 2020 | Supplemental Agreement For Work Within Scope | $16,921,661 |
| VITALANT | CHARACTERIZE SEROPREVALENCE OF SARS COV-2 ANTIBODIES IN THE US POPULATION | May 13, 2020 | $4,515,130 |
About this data
This data comes from the Federal Procurement Data System, which includes all contracts worth $10,000 or more. We look at all contracts that are tagged with the procurement code for COVID-19 or otherwise started in 2020 and contain “COVID-19” in the description. Department of Defense contracting data is subject to a 90-day delay before it appears in the data.